Abiopharma

🔍 Rose Geoffrey Beran (Executive)

Company: Pulmonx Corp (LUNG)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Sold 1,778 shares of Common Stock at $1.54 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 463,956.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,557 shares of Common Stock at $1.54 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 462,399.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,434 shares of Common Stock at $1.54 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 459,965.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 2,254 shares of Common Stock at $1.54 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 457,711.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
• F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
• F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
• F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.